Allogeneic CAR T-cell therapy with ALLO-715 (anti-BCMA) and ALLO-647 (anti-CD52) was well tolerated and showed promising activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
In this updated analysis, patients with a greater proportion of T-cells exhibiting a memory-like phenotype experienced greater CAR T-cell expansion and more durable responses.
Preliminary data from phase I/II study on novel CAR T-cell therapy, P-BCMA-101, suggest safe and effective treatment for relapsed and refractory multiple myeloma.
One-year outcomes from the phase II DREAMM-2 trial showed comparable outcomes with belantamab mafodotin in patients with R/R MM after either 3-6 or ≥ 7 prior lines of therapy.
Preliminary analysis reported manageable safety profile and clinical activity with belantamab mafodotin plus bortezomib/dexamethasone in ongoing phase II trial of pretreated patients with MM.
In patients with R/R MM receiving belantamab mafodotin, ocular AEs were common but manageable, with the majority of patients recovering while remaining on treatment.
Initial results from the phase Ib/II study suggest ciltacabtagene autoleucel, an anti-BCMA CAR T-cell therapy, showed promising efficacy and a manageable safety profile in heavily pretreated patients with R/R MM.
In this early study, the anti-BCMA ADC MEDI228 had manageable toxicity with responses seen at all dose levels in patients with heavily pretreated, relapsed/refractory multiple myeloma.
Subcutaneous administration of teclistamab (JNJ-64007957) was well tolerated and associated with high response rates at the RP2D in an ongoing phase I trial of heavily pretreated patients with multiple myeloma.
Initial results from this ongoing phase I study suggest that once-weekly administration of AMG 701 yields encouraging activity with the possibility for deep, durable responses, along with a manageable safety profile.
After 4 years of follow-up, addition of daratumumab to lenalidomide/dexamethasone reduced the risk of progression or death by 46% and tripled the rate of MRD negativity.
Bispecific antibody targeting GPCR5D, talquetamab, appears tolerable, safe, and efficacious in phase I data in patients with heavily pretreated relapsed/refractory MM.
In this early study, anti-BCMA bispecific antibody REGN5458 showed promising efficacy and safety in heavily pretreated patients with R/R MM.
Novel bispecific antibody targeting FcRH5, cevostamab, active and tolerable in heavily pretreated patients with R/R MM
APOLLO met its primary endpoint of significantly improved PFS with daratumumab SC + Pd vs Pd only in patients with relapsed/refractory MM previously treated with lenalidomide and a PI.
Data from the maintenance phase of GRIFFIN trial with D-VRd + DR maintenance led to significant improvement in sCR and depth of response vs VRd + R maintenance.
The addition of ixazomib to Rd was reasonably well tolerated and conferred a clinically meaningful, but not statistically significant 13.5-month improvement in PFS compared with the control arm.
The first clinical results of iberdomide in combination with either daratumumab/dex or bortezomib/dex is well tolerated with encouraging efficacy in heavily pretreated patients with myeloma.
Combination of belantamab mafodotin with pomalidomide/dexamethasone resulted in high response rates in patients with relapsed/refractory multiple myeloma.
All-oral regimen of selinexor/pomalidomide/low-dose dexamethasone appears to be highly active and have a manageable safety profile in patients with R/R MM after ≥ 2 previous therapies.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.